Alaunos Therapeutics Inc traded at $2.47 this Friday May 15th, decreasing $0.05 or 1.98 percent since the previous trading session. Looking back, over the last four weeks, Alaunos Therapeutics lost 12.72 percent. Over the last 12 months, its price fell by 13.03 percent. Looking ahead, we forecast Alaunos Therapeutics Inc to be priced at 2.42 by the end of this quarter and at 2.28 in one year, according to Trading Economics global macro models projections and analysts expectations.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.